Cannabis
Benchmark Announces Voting Results of the Annual General Meeting of Shareholders
Vancouver, British Columbia–(Newsfile Corp. – October 30, 2020) – Benchmark Botanics, Inc. (CSE: BBT) (FSE: BBW) (“Benchmark” or the “Company“). Benchmark is pleased to announce the results of its annual general meeting of shareholders held on October 29, 2020 (the “Meeting“).
All the resolutions put forward by the Company were approved at the Meeting. The number of directors for the ensuring year has been set at four. Messrs. George Dorin, James Moore, William Ying, and Haifeng Liu were elected directors of the Company and will hold office until the next annual meeting of the Company or until their earlier resignation or removal. Manning Elliott LLP, Chartered Professional Accountants, was re-appointed auditor for the ensuing year.
Detailed results of the vote for the election of directors held at the Meeting are set out below:
Business | Outcome of Vote | Votes For | Votes Against | Votes Withheld |
1. To set the number of Directors | Approved | 95,817,653 (100.00%) |
||
2. Resolution electing: | ||||
(a) George Dorin; | Approved | 95,817,653 (100.00%) |
||
(b) Haifeng Liu; | Approved | 95,817,588 (100.00%) |
65 (0.00%) |
|
(c) James Moore; and | Approved | 95,817,653 (100.00%) |
||
(d) William Ying | Approved | 95,817,588 (100.00%) |
65 (0.00%) |
|
as directors of the Company. | ||||
3. Resolution appointing Manning Elliott LLP, as auditors of the Company for the ensuing year and authorizing the directors of the Company to fix their remuneration. | Approved | 95,817,588 (100.00%) |
65 (0.00%) |
About Benchmark
Benchmark is a diversified multi-licensed cannabis producer focused on a three-way vertical business model targeting the medical and recreational markets in Canada. The Company’s business plan also includes a strategy to become a Canadian licensed producer to pioneer selling medical cannabis and hemp throughout Asia, in countries where it is legal to do so.
Benchmark is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers, as well as developing international business partnerships to extend the Company’s global footprint.
Benchmark’s 100% owned subsidiary, Potanicals Green Growers Inc. (“Potanicals) is a Health Canada licensed producer under the Cannabis Act and its regulations. The Company is producing at its indoor Peachland, BC Cannabis Complex and is constructing a Phase II expansion of an additional 10,000 square foot extraction facility there. Along with cultivation and production, the company’s Peachland BC facility also provides propagation, cultivation, cloning, storage, research and development, genetic improvements.
As part of its expansion strategy, the company and a joint venture partner completed a second facility, a 4-acre Greenhouse Operation in Pitt Meadows, BC. The Company, through Potanicals, has received its second cultivation license, effective November 29, 2019, from Health Canada for the Pitt Meadow greenhouse.
For further information, please visit the Company’s website at www.benchmarkbotanics.com or the Company’s profile at www.sedar.com.
If you would like to be added to Benchmark’s news distribution list, please sign up at Investor Relations [email protected]
ON BEHALF OF THE BOARD OF
BENCHMARK BOTANICS INC.
“William Ying”
William Ying
Chief Executive Officer
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this release.
Forward-Looking Statements
This news release contains forward-looking statements pertaining to various risks and uncertainties regarding future events. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Actual results could differ materially from those currently anticipated due to a number of factors and risks including the risk factors discussed in this news release and in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com and on the CSE website. These statements speak only as of the date of this news release. Except as required by law, the Company does not intend to update these forward-looking statements.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67229
-
Innocan2 weeks ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis2 weeks ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis2 weeks ago
IM Cannabis Reports First Quarter Financial Results
-
Cannabis1 week ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis1 week ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
SCHWAZZE6 days ago
Schwazze Announces First Quarter 2024 Financial Results
-
Cannabis6 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
Cannabis5 days ago
Rubicon Organics Reports Q1 2024 Financial Results